Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Gross Margin (2017 - 2025)

Historic Gross Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 88.07%.

  • UroGen Pharma's Gross Margin fell 22000.0% to 88.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.95%, marking a year-over-year decrease of 23200.0%. This contributed to the annual value of 90.18% for FY2024, which is 14900.0% up from last year.
  • Latest data reveals that UroGen Pharma reported Gross Margin of 88.07% as of Q3 2025, which was down 22000.0% from 85.34% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Gross Margin registered a high of 90.8% during Q1 2024, and its lowest value of 85.34% during Q2 2025.
  • Moreover, its 5-year median value for Gross Margin was 88.76% (2022), whereas its average is 88.73%.
  • In the last 5 years, UroGen Pharma's Gross Margin soared by 39700bps in 2024 and then plummeted by -44600bps in 2025.
  • Over the past 5 years, UroGen Pharma's Gross Margin (Quarter) stood at 90.18% in 2021, then fell by -3bps to 87.49% in 2022, then grew by 3bps to 90.28% in 2023, then decreased by 0bps to 89.94% in 2024, then decreased by -2bps to 88.07% in 2025.
  • Its Gross Margin was 88.07% in Q3 2025, compared to 85.34% in Q2 2025 and 88.5% in Q1 2025.